日本心脏移植受者中依维莫司相关阿弗他口炎的常见发生情况。
Common occurrence of everolimus-associated aphthous stomatitis in Japanese heart transplant recipients.
作者信息
Sasaoka T, Kato T S, Oda N, Wada K, Komamura K, Asakura M, Hashimura K, Ishibashi-Ueda H, Nakatani T, Isobe M, Kitakaze M
机构信息
Department of Cerebral and Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
出版信息
Transplant Proc. 2010 Nov;42(9):3700-3. doi: 10.1016/j.transproceed.2010.06.023.
Mammalian target of rapamycin (mTOR) inhibitors display antiproliferative effects with less nephrotoxicity than calcineurin inhibitors. However, clinical use of mTOR inhibitors can be associated with a series of adverse events. We experienced cases of aphthous stomatitis associated with everolimus (EVL) in four Japanese heart transplant recipients treated at the target trough EVL blood level after a switch from mycophenolate mofetil between April and December 2007. All four patients developed aphthous stomatitis; three required reduction of the exposure and one, EVL discontinuation due to stomatitis as well as other side effects. All patients recovered from stomatitis after reduction or withdrawal of EVL. Thus, we considered that EVL-related stomatitis might occur commonly among the Japanese population. The proper dosage, effects, and frequency of the side effects of mTOR inhibitors may vary by ethnic population.
雷帕霉素哺乳动物靶点（mTOR）抑制剂具有抗增殖作用，且肾毒性比钙调神经磷酸酶抑制剂小。然而，mTOR抑制剂的临床应用可能会伴有一系列不良事件。我们遇到了4例日本心脏移植受者发生阿弗他口炎的病例，这些患者于2007年4月至12月从霉酚酸酯转换为依维莫司（EVL）后，接受了目标EVL血药谷浓度治疗。所有4例患者均出现阿弗他口炎；3例需要减少药物暴露量，1例因口炎及其他副作用而停用EVL。所有患者在减少或停用EVL后口炎均痊愈。因此，我们认为EVL相关的口炎可能在日本人群中普遍发生。mTOR抑制剂的合适剂量、效果及副作用发生频率可能因种族人群而异。
Zotero 插件